Today's alert for members contains an assessment of the recently published Listed medicines Evidence Guidelines; a summary of CMA responses and outcomes; and a discussion of changes and issues for members to be aware of.

A full comparison highlighting the changes between the final published guidelines and the draft consultation paper is also linked for members.

We appreciate and welcome your ongoing member feedback and insights.